http://www.creativebiomart.net/description_382816_12.htm

Tyrosine-protein kinase 6 (PTK6), also known as Breast tumor Kinase (BRK), is a Src-like nonreceptor tyrosine kinase, which belongs to Tyr protein kinase family. It is overexpressed in the majority of breast cancer and several other cancer types, while being detected at appreciable levels in only a limited range of adult tissues that does not include the mammary gland. PTK6 contains SH3, SH2, and Kinase domains, with a linker region (Linker) between the SH2 and Kinase domains, and the structural basis of the SH3-Linker interaction that results in auto-inhibition of PTK6. Human PTK6 is 79% aa identical to mouse PTK6. PTK6 has been shown to interact with STAP2 and KHDRBS1. In ErbB-Brk-Rac-p38 MAPK pathway, PTK6 is a critical mediator of breast cancer cell migration. The effect of PTK6 on the regulation of phosphoinositide 3-kinase and Akt activity may account for PTK6s ability to enhance mammary cell mitogenesis, raises the possibility that breast tumours. PTK6 is implicated in EGF receptor-dependent signalling and epithelial tumorigenesis. As a stress-induced kinase, it promotes apoptosis by inhibiting prosurvival signaling. In addition, PTK6 may play a key role in lymphomagenesis, hence identifying the kinase as a potential therapeutic target in lymphomas.